Related Experiment Video
Updated: Jul 6, 2025
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Pharmacological and clinical appraisal of factor XI inhibitor drugs
Giovanni Occhipinti1, Claudio Laudani1, Marco Spagnolo1
1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-San Marco", University of Catania, Catania 95123, Italy.
Abstract:
The evolution of anticoagulation therapy, from vitamin K antagonists to the advent of direct oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite improved safety demonstrated in pivotal trials and post-marketing observations, persistent concerns exist, particularly regarding bleeding risk and the absence of therapeutic indications in specific subgroups or clinical contexts. Factor XI (FXI) has recently emerged as a pivotal contributor to intraluminal thrombus formation and growth, playing a limited role in sealing vessel wall injuries. Inhibiting FXI presents an opportunity to decouple thrombosis from haemostasis, addressing concerns related to bleeding events while safeguarding against thromboembolic events. Notably, FXI inhibition holds promise for patients with end-stage renal disease or cancer, where clear indications for DOACs are currently lacking. Various compounds have undergone design, testing, and progression to phase 2 clinical trials, demonstrating a generally favourable safety and tolerability profile. However, validation through large-scale phase 3 trials with sufficient power to assess both safety and efficacy outcomes is needed. This review comprehensively examines FXI inhibitors, delving into individual classes, exploring their pharmacological properties, evaluating the latest evidence from randomized trials, and offering insights into future perspectives.
Insights
New Factor XI (FXI) inhibitors offer a promising anticoagulation strategy, potentially reducing bleeding risks and addressing unmet needs in specific patient groups. Further phase 3 trials are crucial for validation.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Anticoagulation therapy has evolved from vitamin K antagonists to direct oral anticoagulants (DOACs).
- Despite DOAC advancements, concerns persist regarding bleeding risks and limited indications in certain patient populations.
- Factor XI (FXI) plays a key role in thrombus formation with less involvement in hemostasis, presenting a novel therapeutic target.
Purpose of the Study:
- To review the development and clinical evidence of Factor XI (FXI) inhibitors.
- To explore the pharmacological properties and therapeutic potential of FXI inhibitors.
- To discuss the future perspectives of FXI inhibition in anticoagulation.
Main Methods:
- Comprehensive review of existing literature on FXI inhibitors.
- Analysis of data from randomized clinical trials, including phase 2 studies.
- Examination of pharmacological profiles and safety/efficacy data.
Main Results:
- FXI inhibitors demonstrate a generally favorable safety and tolerability profile in early trials.
- Targeting FXI offers a potential to decouple thrombosis from hemostasis, reducing bleeding risk.
- FXI inhibition shows promise for patients with end-stage renal disease and cancer, where DOAC indications are lacking.
Conclusions:
- FXI inhibitors represent a significant advancement in anticoagulation, potentially offering a safer alternative to current therapies.
- Further large-scale phase 3 trials are necessary to confirm the efficacy and safety of FXI inhibitors.
- FXI inhibition may address critical unmet needs in anticoagulation for specific patient subgroups.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:13Therapeutic Index
01:16Clot Retraction and Fibrinolysis